98%
921
2 minutes
20
The Apl protein of bacteriophage 186 functions both as an excisionase and as a transcriptional regulator; binding to the phage attachment site (att), and also between the major early phage promoters (pR-pL). Like other recombination directionality factors (RDFs), Apl binding sites are direct repeats spaced one DNA helix turn apart. Here, we use in vitro binding studies with purified Apl and pR-pL DNA to show that Apl binds to multiple sites with high cooperativity, bends the DNA and spreads from specific binding sites into adjacent non-specific DNA; features that are shared with other RDFs. By analysing Apl's repression of pR and pL, and the effect of operator mutants in vivo with a simple mathematical model, we were able to extract estimates of binding energies for single specific and non-specific sites and for Apl cooperativity, revealing that Apl monomers bind to DNA with low sequence specificity but with strong cooperativity between immediate neighbours. This model fit was then independently validated with in vitro data. The model we employed here is a simple but powerful tool that enabled better understanding of the balance between binding affinity and cooperativity required for RDF function. A modelling approach such as this is broadly applicable to other systems.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498355 | PMC |
http://dx.doi.org/10.1093/nar/gkaa655 | DOI Listing |
RMD Open
September 2025
Department of Rheumatology, Oslo University Hospital, Oslo, Norway.
Objective: This population-based study aimed to determine timing and incidence of arterial and venous thromboembolic events (TE) and antiphospholipid syndrome (APS) relative to systemic lupus erythematosus (SLE) onset and assess relationships between TE, APS and anti-phospholipid antibodies (aPL) during follow-up.
Methods: We included all medical-record confirmed new-onset SLE patients in Southeast Norway (population 2.9 million) 2000-2017 who fulfilled the 2019 European Alliance of Rheumatology Associations/American College of Rheumatology classification criteria.
Sao Paulo Med J
September 2025
Physician, Departamento de Obstetrícia, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro (RJ), Brazil.
Background: Pregnant women are at an increased risk of thromboembolism compared with non-pregnant women. Venous thrombosis is a manifestation of antiphospholipid syndrome (APS), an autoimmune thrombophilia associated with pregnancy morbidity.
Objectives: This study was designed to compare gestational outcomes of pregnant patients with deep venous thrombosis (DVT) and primary APS with outcomes of patients with DVT and negative results for antiphospholipid antibodies (aPLs).
Georgian Med News
June 2025
6Municipal State Enterprise "City Center for Human Reproduction" under the Public Health Department, Almaty, Kazakhstan.
Introduction: Antiphospholipid syndrome is an autoimmune disease marked by antiphospholipid antibodies, causing thrombosis and obstetric complications.
Objectives: This study explores molecular mechanisms, endometrial receptivity, and clinical parameters linked to APS, focusing on pregnancy complications such as miscarriage, preterm delivery, recurrent implantation failure (RIF), and thrombosis.
Patients And Methods: A systematic review was conducted through Scopus, WoS, PubMed, Cochrane, and Google Scholar, including studies published between 2019 and 2024.
Front Immunol
August 2025
Center for Cardiovascular and Nutrition research (C2VN), Institut national de recherche pour l'agriculture et l'alimentation (INRA) 1260, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1263, Aix-Marseille University, Marseille, France.
Introduction: Long COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determine if the presence of aPL was associated with the progression towards long COVID.
View Article and Find Full Text PDFFront Immunol
August 2025
Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Introduction: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic symptoms (venous, arterial, or small vessels) and/or gestational morbidity in patients carrying antiphospholipid antibodies (aPLs). Criteria aPLs include anti-cardiolipin antibodies, anti-beta 2 glycoprotein I (aB2GPI) antibodies of the IgG or IgM isotypes, and lupus anticoagulant (LA). However, there are aPLs that are associated with APS events but are not included in the criteria (extra-criteria).
View Article and Find Full Text PDF